ARQT — Arcutis Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1787306 ·
Last close
$27.33
Market Cap
$3.46B
52W High
$34.80
52W Low
$19.30
ADV30
2,397,328
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 143,919,000 | 131,459,000 | 9,436,000 | 8,801,000 | 524,426,000 | 33,373,000 | 280,460,000 |
| Jun 2026 | 129,861,000 | 118,922,000 | 16,429,000 | 15,009,000 | 488,537,000 | 34,121,000 | 267,958,000 |
| Mar 2026 | 105,398,000 | 95,614,000 | -9,089,000 | -11,295,000 | 460,003,000 | 34,762,000 | 270,355,000 |
| Dec 2025 | 129,503,000 | 117,815,000 | 18,387,000 | 17,395,000 | 432,973,000 | 42,907,000 | 243,494,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$59,961,000
Investing CF
$-82,819,000
Financing CF
$9,232,000
CapEx
$-10,783,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.21
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,125,569,000
Inventory
$45,669,000
Receivables
$171,281,000
ST Investments
$226,087,000
EBIT TTM
$44,538,000
Pretax Income TTM
$30,804,000
Interest Exp TTM
$13,734,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$508,680,992
EBITDA
$37,413,000
Free Cash Flow
$32,623,124
Enterprise Value
$3,095,286,016
Total Cash
$259,460,000
Total Debt
$123,820,000
Shares Out
126,455,033
Trailing EPS
$0.22
Book Value
$1.94
ROE
14.9%
ROA
4.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 376,072,000 | -12,227,000 | -16,141,000 | 432,973,000 | 243,494,000 | 189,479,000 | -5,625,000 |
| Dec 2024 | 196,542,000 | -128,397,000 | -140,039,000 | 348,889,000 | 191,348,000 | 157,541,000 | -112,158,000 |
| Dec 2023 | 59,606,000 | -241,101,000 | -262,140,000 | 341,365,000 | 252,698,000 | 88,667,000 | -247,057,000 |
| Dec 2022 | 3,686,000 | -301,627,000 | -311,458,000 | 449,274,000 | 239,693,000 | 209,581,000 | -257,715,000 |
TTM Snapshot
Revenues TTM
$463,981,000
NetIncome TTM
$28,519,000
OpCashFlow TTM
—
Assets (Latest)
$488,537,000
Forward EPS
$1.34
Max Pain — expiry 2027-01-15
max pain strike: $15.00 · spot: $27.61 · call oi: 3,999 · put oi: 261
Expected Move to 2027-01-15:
±$5.58
(20.19%) —
implied range
$22.04 –
$33.19
· ATM straddle on $27.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ELVN | Enliven Therapeutics, Inc. | $3.45B | $46.85 | — |
| VKTX | Viking Therapeutics, Inc. | $3.43B | $26.88 | — |
| IRON | Disc Medicine, Inc. | $3.49B | $76.57 | — |
| PBLS | Parabilis Medicines, Inc. | $3.49B | $28.25 | — |
| VRDN | Viridian Therapeutics, Inc.\DE | $3.41B | $30.06 | — |
News headlines (Yahoo Finance, 1h cache)
Arcutis Biotherapeutics (ARQT) Stock Looks Expensive Despite Its Huge Three Year Run
2026-11-14 01:16 · Yahoo
Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Mee
2026-11-13 14:00 · Yahoo
Arcutis Biotherapeutics Inc (ARQT) (Q3 2026) Earnings Call Highlights: Revenue Surges 45% to ...
2026-11-07 23:08 · Yahoo
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 21:00 · Yahoo
Arcutis Biotherapeutics (ARQT) Raised 2026 Sales Guidance, Is The Upside Already Priced In?
2026-11-06 10:14 · Yahoo
Biotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?
2026-11-05 21:22 · Yahoo
Arcutis Biotherapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-05 13:30 · Yahoo
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
2026-11-05 13:00 · Yahoo
Arcutis Biotherapeutics Q3 Earnings Call Highlights
2026-11-05 00:14 · Yahoo
Arcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings Estimates
2026-11-04 21:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.